SOM Biotech (www.sombiotech.com) is a global leader in the field of Repurposing drugs for Orphan Indications. Founded in 2009 in Barcelona, Spain, SOM is also headquartered in Cambridge, Massachusetts. The Company has a strong pipeline of products focused on CNS at preclinical and clinical stages. The most advanced asset is SOM3355 for Huntington’s disease and other hyperkinetic movement disorders currently under Phase 2, along with SOM1201 for Adrenoleukodystrophy also in clinical stage. Several more products are in preclinical, including Duchenne Muscular Distrophy, Glioblastoma and more. SOM Biotech’s drug discovery is based on a proprietary drug repurposing tool. This has demonstrated success versus other platforms already achieving one strong validation from licensing our first drug candidate, SOM0226, for TTR Amyloidosis. We also collaborate with pharma companies willing to repurpose their own drugs or find candidates for their specific therapeutic area.